Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - eye drops - 1.5mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - eye drops - 3mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - oral solution - 100mg/1ml

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - lozenge - 10mg

Malta - angličtina - Medicines Authority

gilead sciences ireland uc carrigtohill, country cork, , ireland - amphotericin b - powder for concentrate for dispersion for infusion - amphotericin b 50 milligram(s) - antimycotics for systemic use

Spojené kráľovstvo - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - amphotericin b - solution for injection - 50microgram/1ml

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

gilead sciences (nz) - amphotericin b 50mg - powder for injection - 50 mg - active: amphotericin b 50mg excipient: cholesterol hydrochloric acid alpha-tocopherol distearoylphosphatidylglycerol phosphatidylcholines, soya, hydrogenated phosphatidylglycerols as sodium salt sodium hydroxide sodium succinate sucrose - ambisome is indicated for: · prophylaxis in liver transplant patients at risk of systemic candida, aspergillus and cryptococcus infections, and for · the treatment of systemic fungal infections caused by organisms susceptible to amphotericin b. ambisome is indicated for empirical treatment of presumed fungal infections in febrile neutropaenic patients whose fever has failed to respond to broad spectrum antibiotic treatment. ambisome is indicated for the treatment of visceral leishmaniasis. clinical studies of efficacy in visceral leishmaniasis are limited to leishmania infantum.

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - amphotericin b, quantity: 10 mg - lozenge - excipient ingredients: acacia; mannitol; polyvinyl alcohol; saccharin sodium; sodium cyclamate; purified talc; stearic acid; flavour - treatment of candidal infections of the oral and perioral areas including oral thrush, angular cheilitis, denture stomatitis and in other conditions of the mouth, throat and tongue complicated by the overgrowth of candida albicans.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - amphotericin b 5 mg/ml (as a lipid complex; for manufacture see dmf tt60-104-24-4);   - emulsion for infusion - 5 mg/ml - active: amphotericin b 5 mg/ml (as a lipid complex; for manufacture see dmf tt60-104-24-4)   excipient: dimyristoylphosphatidylcholine dimyristoylphosphatidylglycerol as sodium and ammonium salts sodium chloride water for injection - abelcet is indicated for the treatment of invasive fungal disease caused by organisms susceptible to amphotericin b.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - amphotericin b 10mg (overage of 20% (12mg)) - lozenge - 10 mg - active: amphotericin b 10mg (overage of 20% (12mg)) excipient: acacia curacao flavour 50397 ap0500 mannitol orange flavour orange flavour 051226t polyvinyl alcohol purified talc saccharin sodium sodium cyclamate stearic acid - for the treatment of candidal lesions (thrush) of the oral and perioral areas.